Evidence map›Paper›PMID 38477209›Full record

ReviewCurrent pharmaceutical design2024

Relationship between Compound α-Ketoacid and Microinflammation in Patients with Chronic Kidney Disease.

Zaobin Chen, Yongda Lin, Jiali Wang, Kaijin Yao, Yina Xie, Xiutian Chen, Tianbiao Zhou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zaobin ChenDepartment of Nephrology, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Yongda LinDepartment of Nephrology, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Jiali WangDepartment of Nephrology, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Kaijin YaoDepartment of Nephrology, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Yina XieDepartment of Nephrology, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Xiutian ChenDepartment of Nephrology, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Tianbiao ZhouDepartment of Nephrology, The Second Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
Second Affiliated Hospital of Shantou University Medical College · CNShantou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) refers to the presence of structural or functional abnormalities in the kidneys that affect health, lasting for more than 3 months. CKD is not only the direct cause of global incidence rate and mortality, but also an important risk factor for cardiovascular disease. Persistent microinflammatory state has been recognized as an important component of CKD, which can lead to renal fibrosis and loss of renal function, and plays a crucial role in the pathophysiology and progression of the disease. Simultaneously, compound α-Ketoacid can bind nitrogen-containing metabolites in the blood and accelerate their excretion from the body, thereby reducing the level of metabolic waste, alleviating gastrointestinal reactions in patients, and reducing the inflammatory response and oxidative stress state of the body. Compound α-Ketoacid contains amino acids required by CKD patients. In this review, we explore the relationship between compound α-Ketoacid and microinflammation in patients with CKD. The review indicated that compound α-Ketoacid can improve the microinflammatory state in CKD patients by improving the nutritional status of CKD patients, improving patient's acid-base balance disorder, regulating oxidative stress, improving gut microbiota, and regulating abnormal lipid metabolism.

Indexed as

InflammationKeto AcidsRenal Insufficiency, ChronicHumansOxidative StressKeto Acidsabnormal lipid metabolism.chronic kidney diseaseCompound α-Ketoacidgut microbiotamicro inflammatorynitrogen-containing metabolitesoxidative stress

Identifiers

PMID38477209
OpenAlexW4392052932

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.